

## Report of Organizational Actions Affecting Basis of Securities

▶ See separate instructions.

**Part I Reporting Issuer**

1 Issuer's name <b>Leap Therapeutics, Inc.</b>		2 Issuer's employer identification number (EIN) <b>27-4412575</b>	
3 Name of contact for additional information <b>Douglas E. Onsi</b>	4 Telephone No. of contact <b>617-714-0360</b>	5 Email address of contact <b>info@leaptx.com</b>	
6 Number and street (or P.O. box if mail is not delivered to street address) of contact <b>47 Thorndike Street, Suite B1</b>		7 City, town, or post office, state, and ZIP code of contact <b>Cambridge, MA 02141</b>	
8 Date of action <b>June 21, 2023</b>		9 Classification and description <b>One-for-ten reverse stock split of issued and outstanding common stock</b>	
10 CUSIP number <b>52187K200</b>	11 Serial number(s)	12 Ticker symbol <b>LPTX</b>	13 Account number(s)

**Part II Organizational Action** Attach additional statements if needed. See back of form for additional questions.

14 Describe the organizational action and, if applicable, the date of the action or the date against which shareholders' ownership is measured for the action ▶

**Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immunooncology therapeutics, effected a 10-for-1 reverse stock split of its issued and outstanding common stock, effective at 5PM ET on June 20, 2023. Leap's common stock began trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on June 21, 2023. Leap's stockholders approved the reverse stock split during its 2023 Annual Meeting of Stockholders on June 16, 2023 and granted the Board of Directors authorization to determine the final ratio for the split. The reverse stock split was implemented to increase the per share trading price of the Company's common stock to meet the minimum Nasdaq listing price per share requirements and to decrease the number of shares outstanding in order to facilitate the conversion of the Series X Non-Voting Convertible Preferred Stock into common stock at 5PM ET on June 21, 2023. Leap's common stock will continue to trade on the Nasdaq Capital Market under the symbol "LPTX" following the reverse stock split, with a new CUSIP number of 52187K 200. As a result of the reverse stock split, every 10 shares of Leap's common stock issued and outstanding was automatically reclassified into one new share of common stock.**

15 Describe the quantitative effect of the organizational action on the basis of the security in the hands of a U.S. taxpayer as an adjustment per share or as a percentage of old basis ▶

**Under Internal Revenue Code (IRC) Section 305(a), the reverse split is a nontaxable transaction. Under IRC Section 307(a), each shareholder is required to allocate the aggregate cost basis in their shares immediately prior to the one for ten reverse split among their number of shares held immediately after the reverse split. As a result, the number of shares held by each shareholder were effectively divided by ten, and accordingly, the cost basis per share is multiplied by ten to arrive at the cost basis per share after the reverse split.**

16 Describe the calculation of the change in basis and the data that supports the calculation, such as the market values of securities and the valuation dates ▶

**As a result, the number of shares held by each shareholder were effectively divided by ten and accordingly, the cost basis per share is multiplied by ten to arrive at the cost basis per share after the reverse split.**

